Weekly Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings as of May 17, 2018

May 17, 2018 - By Kenneth Sanchez

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Corporate Logo
Big Money Sentiment increased to 3 in 2017 Q4. It has change of 2.21, from 2017Q3’s 0.79. The ratio improved due to Dicerna Pharmaceuticals, Inc. positioning: 6 sold and 5 reduced. 18 funds bought stakes and 15 increased stakes. Investors holded 10.37 million in 2017Q3 but now own 29.10 million shares or 180.62% more.
Royal Bankshares Of Canada holds 0% or 1,016 shs. Jpmorgan Chase has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Renaissance Ltd Liability Co accumulated 560,300 shs. Goldman Sachs Group reported 194,198 shs. First Manhattan Comm stated it has 428,100 shs or 0.02% of all its holdings. Camber Cap Management Limited Liability Com has 0.44% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). State Street has 10,321 shs. Palo Alto Limited Liability Com reported 500,913 shs. California Pub Employees Retirement Systems holds 41,000 shs or 0% of its capital. 7,533 are held by Panagora Asset Management Inc. Bancorporation Of Ny Mellon Corp owns 19,579 shs or 0% of their US capital. Deutsche Bancorporation Ag owns 168,400 shs. Bridger Mngmt Limited Liability Co owns 905,998 shs for 0.54% of their capital. Retail Bank Of America Corp De holds 35 shs or 0% of its capital. Birchview Capital Limited Partnership, Vermont-based fund reported 45,000 shs.

Dicerna Pharmaceuticals, Inc. registered $1.57 million net activity with 1 buy and 4 sales since December 18, 2017. $145,035 worth of stock was sold by Brown Bob D on Wednesday, May 9. $2.00M worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was bought by Bain Capital Life Sciences Investors – LLC.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Ratings Coverage

A total of 8 analysts rate Dicerna Pharmaceuticals (NASDAQ:DRNA) as follows: 4 “Buy”, 4 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NASDAQ:DRNA) has 8 ratings reports on May 17, 2018 according to StockzIntelligence. In Monday, February 5 report SunTrust initiated it with “Buy” rating and $13.0 target. On Tuesday, March 27 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Hold” rating given by FBR Capital. On Friday, March 9 the firm has “Hold” rating by Chardan Capital Markets given. On Friday, March 23 the stock has “Neutral” rating by H.C. Wainwright. On Friday, March 9 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has “Buy” rating given by Stifel Nicolaus. On Wednesday, April 11 the stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Cowen & Co. Listed here are Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) PTs and latest ratings.

11/04/2018 Broker: Cowen & Co Rating: Buy Initiate
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $10 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $10.0000 Initiate
23/03/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Neutral Old Target: $7 Downgrade
09/03/2018 Broker: Chardan Capital Markets Rating: Hold Initiate
09/03/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $10 New Target: $17 Maintain
05/02/2018 Broker: SunTrust Rating: Buy New Target: $13.0 Initiate
16/01/2018 Broker: Evercore Rating: Outperform New Target: $14 Initiates Coverage On

Ticker’s shares touched $13.76 during the last trading session after 0.04% change.Dicerna Pharmaceuticals, Inc. has volume of 29,107 shares. Since May 17, 2017 DRNA has risen 274.53% and is uptrending. DRNA outperformed the S&P 500 by 262.98%.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally.The firm is worth $712.73 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases.Currently it has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.

More recent Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) news were brought out by Streetinsider.com, Businesswire.com and Benzinga.com. The first one has “Dicerna Pharmaceuticals (DRNA) PT Raised to $18 at Stifel” as a title and was brought out on May 15, 2018. The next is “Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update” on May 14, 2018. And last was brought out on May 14, 2018, called “Earnings Scheduled For May 14, 2018”.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.